Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors

US7528255B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Bernd Riedl · Wuppertal, DE
• Jacques Dumas · Neuilly-Plaisance, FR
• Uday Khire · Hamden, US
• Timothy B. Lowinger · Carlisle, US
• William Scott · Guilford, US
• Roger Smith · Madison, US
• Jill Wood · Hampton, US

Key dates

• Filing date: Feb 11, 2002
• Grant date: May 5, 2009
• Expiry date: Nov 6, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/1804
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula